Pharma & Biotech News , from our Global Correspondents
Refine search
Pharmaceutical
Russia is considering a significant increase public procurements of drugs for the treatment of obesity within the next several years, reports The Pharma Letter’s local correspondent. 17 July 2026
Pharmaceutical
Latin American countries need to treat health spending as an investment rather than a cost if they are to expand coverage, strengthen health systems and support broader economic development, according to the Latin American Federation of the Pharmaceutical Industry, FIFARMA. 16 July 2026
Pharmaceutical
Leading Russian drugmakers are considering accelerating their expansion into the African region this year that will take place through the supplies of their drugs to the continent and building of their production facilities there, reports The Pharma Letter’s local correspondent. 13 July 2026
Pharmaceutical
The Russian government plans to postpone the introduction of "second-extra" rule for vital drugs during public procurements until December, reports The Pharma Letter’s local correspondent. 10 July 2026
Generics
India has renewed its call for broader pharmaceutical market access in China, arguing that deeper commercial engagement between the two countries is necessary despite, and in some ways because of, the sharply skewed trade numbers that continue to define bilateral pharmaceutical ties, reports The Pharma Letter’s India correspondent. 8 July 2026
Pharmaceutical
The Russian Supreme Court has refused to review the dispute of UK pharma major AstraZeneca with the Russian drugmaker Akrikhin dispute over Forxiga (dapagliflozin) - a drug for the treatment of type 2 diabetes – that became a response to the cassation appeal, which was earlier filed by AstraZeneca. 6 July 2026
Pharmaceutical
Russian pharmaceutical companies and global drugmakers operating in the local market have called on the national government to speed the process of entering new drugs in public procurements after their registration, reports The Pharma Letter’s local correspondent. 3 July 2026
Pharmaceutical
India’s pharmaceutical industry is witnessing a surge in global partnerships, with countries such as Switzerland, Uzbekistan, and Japan stepping up collaboration. 29 June 2026
Generics
The Russian Patent and Trademark Office refused to overturn the patent for the anticoagulant apixaban, which is owned by US pharma major Bristol Myers Squibb on the basis of the claim filed by the Israeli pharmaceutical company Teva Pharmaceutical Industries, reports The Pharma Letter’s local correspondent. 25 June 2026
Pharmaceutical
Russian biopharmaceutical company Nanolek will launch armocibart, a hemophilia drug that was developed by Chinese company Suzhou Alphamab, in Russia and several other countries, reports The Pharma Letter’s local correspondent. 24 June 2026
Generics
India is grappling with a severe shortage of two cornerstone chemotherapy drugs, cisplatin and carboplatin, as soaring platinum prices, higher import duties, and regulatory delays make production financially unsustainable. 16 June 2026
Pharmaceutical
Russian drugmaker Pharmstandard plans to build a new complex for the production of live vaccines in the Technopolis special economic zone in the Moscow region, which is expected to be one of the largest of such kind in the country, reports The Pharma Letter’s local correspondent. 15 June 2026
Generics
In a significant move to expand its oncology footprint in the United States, Indian major Dr Reddy’s Laboratories has announced the launch of Bosutinib 400mg tablets, the generic equivalent of Pfizer’s blockbuster drug Bosulif, used in the treatment of chronic myeloid leukemia (CML). 15 June 2026
Generics
Russian pharmaceutical company KhimRar Group is expanding its capacities for the production of active pharmaceutical ingredients (APIs) by 10 times up to 50 tons per year, reports The Pharma Letter’s local correspondent. 8 June 2026
Generics
Russia will have its own generic of one of the world’s most expensive drug against cystic fibrosis, as the Russian pharmaceutical company Amedart announced its plans launch a domestic analogue of Trikafta (elexacaftor/tezacaftor/ivacaftor), a drug from the American company Vertex Pharmaceuticals for the treatment of cystic fibrosis, reports The Pharma Letter’s local correspondent. 5 June 2026
Biotechnology
India’s biotechnology sector is entering a transformative phase, with domestic and global players betting on the country’s scientific talent and cost advantages to make advanced therapies such as CAR-T cell therapy more accessible, reports The Pharma Letter’s India correspondent. 1 June 2026
Generics
Indian pharmaceutical companies have pledged an unprecedented $19.1 billion in investments across the USA, marking a watershed moment in bilateral healthcare collaboration. 11 May 2026
Generics
The share of generics in the Russian pharmaceutical market will grow in the coming years, both in the pharmacy segment and in government procurement, according to latest forecasts made by experts of the Russian analyst agency in the field of pharmaceutics DSM Group. 11 May 2026
Generics
Russia is experiencing a boom of sales of obesity drugs, which is mainly due to the recent launch of some domestically developed drugs in this market segment, reports The Pharma Letter’s local correspondent. 8 May 2026
Biotechnology
Russia has faced an acute shortage of Abraxane (paclitaxel), a drug, which is produced by US pharma major Bristol-Myers Squibb and which is designed for the treatment of patients with breast and pancreatic cancer, The Pharma Letter’s local correspondent reports. 5 May 2026
Pharmaceutical
Russia is considering a significant increase public procurements of drugs for the treatment of obesity within the next several years, reports The Pharma Letter’s local correspondent. 17 July 2026
Pharmaceutical
Latin American countries need to treat health spending as an investment rather than a cost if they are to expand coverage, strengthen health systems and support broader economic development, according to the Latin American Federation of the Pharmaceutical Industry, FIFARMA. 16 July 2026
Pharmaceutical
Leading Russian drugmakers are considering accelerating their expansion into the African region this year that will take place through the supplies of their drugs to the continent and building of their production facilities there, reports The Pharma Letter’s local correspondent. 13 July 2026
Pharmaceutical
The Russian government plans to postpone the introduction of "second-extra" rule for vital drugs during public procurements until December, reports The Pharma Letter’s local correspondent. 10 July 2026
Generics
India has renewed its call for broader pharmaceutical market access in China, arguing that deeper commercial engagement between the two countries is necessary despite, and in some ways because of, the sharply skewed trade numbers that continue to define bilateral pharmaceutical ties, reports The Pharma Letter’s India correspondent. 8 July 2026
Pharmaceutical
The Russian Supreme Court has refused to review the dispute of UK pharma major AstraZeneca with the Russian drugmaker Akrikhin dispute over Forxiga (dapagliflozin) - a drug for the treatment of type 2 diabetes – that became a response to the cassation appeal, which was earlier filed by AstraZeneca. 6 July 2026
Pharmaceutical
Russian pharmaceutical companies and global drugmakers operating in the local market have called on the national government to speed the process of entering new drugs in public procurements after their registration, reports The Pharma Letter’s local correspondent. 3 July 2026
Pharmaceutical
India’s pharmaceutical industry is witnessing a surge in global partnerships, with countries such as Switzerland, Uzbekistan, and Japan stepping up collaboration. 29 June 2026
Generics
The Russian Patent and Trademark Office refused to overturn the patent for the anticoagulant apixaban, which is owned by US pharma major Bristol Myers Squibb on the basis of the claim filed by the Israeli pharmaceutical company Teva Pharmaceutical Industries, reports The Pharma Letter’s local correspondent. 25 June 2026
Pharmaceutical
Russian biopharmaceutical company Nanolek will launch armocibart, a hemophilia drug that was developed by Chinese company Suzhou Alphamab, in Russia and several other countries, reports The Pharma Letter’s local correspondent. 24 June 2026
Generics
India is grappling with a severe shortage of two cornerstone chemotherapy drugs, cisplatin and carboplatin, as soaring platinum prices, higher import duties, and regulatory delays make production financially unsustainable. 16 June 2026
Pharmaceutical
Russian drugmaker Pharmstandard plans to build a new complex for the production of live vaccines in the Technopolis special economic zone in the Moscow region, which is expected to be one of the largest of such kind in the country, reports The Pharma Letter’s local correspondent. 15 June 2026
Generics
In a significant move to expand its oncology footprint in the United States, Indian major Dr Reddy’s Laboratories has announced the launch of Bosutinib 400mg tablets, the generic equivalent of Pfizer’s blockbuster drug Bosulif, used in the treatment of chronic myeloid leukemia (CML). 15 June 2026
Generics
Russian pharmaceutical company KhimRar Group is expanding its capacities for the production of active pharmaceutical ingredients (APIs) by 10 times up to 50 tons per year, reports The Pharma Letter’s local correspondent. 8 June 2026
Generics
Russia will have its own generic of one of the world’s most expensive drug against cystic fibrosis, as the Russian pharmaceutical company Amedart announced its plans launch a domestic analogue of Trikafta (elexacaftor/tezacaftor/ivacaftor), a drug from the American company Vertex Pharmaceuticals for the treatment of cystic fibrosis, reports The Pharma Letter’s local correspondent. 5 June 2026
Biotechnology
India’s biotechnology sector is entering a transformative phase, with domestic and global players betting on the country’s scientific talent and cost advantages to make advanced therapies such as CAR-T cell therapy more accessible, reports The Pharma Letter’s India correspondent. 1 June 2026
Generics
Indian pharmaceutical companies have pledged an unprecedented $19.1 billion in investments across the USA, marking a watershed moment in bilateral healthcare collaboration. 11 May 2026
Generics
The share of generics in the Russian pharmaceutical market will grow in the coming years, both in the pharmacy segment and in government procurement, according to latest forecasts made by experts of the Russian analyst agency in the field of pharmaceutics DSM Group. 11 May 2026
Generics
Russia is experiencing a boom of sales of obesity drugs, which is mainly due to the recent launch of some domestically developed drugs in this market segment, reports The Pharma Letter’s local correspondent. 8 May 2026
Biotechnology
Russia has faced an acute shortage of Abraxane (paclitaxel), a drug, which is produced by US pharma major Bristol-Myers Squibb and which is designed for the treatment of patients with breast and pancreatic cancer, The Pharma Letter’s local correspondent reports. 5 May 2026
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2026
| Headless Content Management with Blaze